GeneDx (WGS) Set to Announce Earnings on Monday

GeneDx (NASDAQ:WGS) is scheduled to be announcing its earnings results after the market closes on Monday, April 29th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. GeneDx has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.01. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. The company had revenue of $57.42 million for the quarter, compared to the consensus estimate of $57.00 million. On average, analysts expect GeneDx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GeneDx Trading Down 0.8 %

Shares of WGS stock opened at $11.08 on Friday. GeneDx has a 12 month low of $1.16 and a 12 month high of $12.57. The company has a quick ratio of 2.95, a current ratio of 3.10 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average is $9.27 and its two-hundred day moving average is $5.01. The company has a market cap of $288.63 million, a PE ratio of -1.49 and a beta of 2.75.

Insider Buying and Selling

In related news, Director Casdin Capital, Llc acquired 40,000 shares of the business’s stock in a transaction on Monday, March 4th. The stock was bought at an average cost of $8.74 per share, with a total value of $349,600.00. Following the completion of the acquisition, the director now owns 2,702,609 shares in the company, valued at $23,620,802.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Kevin Feeley sold 3,253 shares of GeneDx stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $10.59, for a total value of $34,449.27. Following the completion of the transaction, the chief financial officer now directly owns 28,927 shares of the company’s stock, valued at $306,336.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Casdin Capital, Llc acquired 40,000 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was purchased at an average price of $8.74 per share, with a total value of $349,600.00. Following the completion of the transaction, the director now owns 2,702,609 shares of the company’s stock, valued at $23,620,802.66. The disclosure for this purchase can be found here. Insiders sold a total of 13,820 shares of company stock valued at $146,354 over the last ninety days. 28.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

WGS has been the topic of several research analyst reports. The Goldman Sachs Group raised their price objective on shares of GeneDx to $11.00 and gave the stock a “neutral” rating in a research note on Monday, April 15th. BTIG Research raised their price objective on shares of GeneDx from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, April 22nd.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.